Sino Biopharmaceutical Limited
1177
Rang in Aktien
#1766
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Aktienkurs
$0.68180748
Marktkapitalisierung
$12.14B
Veränderung (1 Tag)
-1.30%
Veränderung (1 Jahr)
-28.39%
Land
HK
Handel Sino Biopharmaceutical Limited (1177)
Kategorie
Healthcare
Umsatz von Sino Biopharmaceutical Limited (1177)
Umsatz im Jun 2026 TTM: $4.88B
Laut den aktuellen Finanzberichten von Sino Biopharmaceutical Limited beträgt der derzeitige Umsatz des Unternehmens (TTM) $4.88B. Im Jahr 2023 erzielte das Unternehmen einen Umsatz von $3.70B ein Rückgang im Vergleich zu dem Umsatz im Jahr 2022, der $3.77B betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Sino Biopharmaceutical Limited von 2000 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $4.88B | 23.50% |
| 2024 | $3.95B | 6.85% |
| 2023 | $3.70B | -1.90% |
| 2022 | $3.77B | -10.72% |
| 2021 | $4.23B | 16.75% |
| 2020 | $3.62B | 4.01% |
| 2019 | $3.48B | 14.60% |
| 2018 | $3.04B | 33.32% |
| 2017 | $2.28B | 11.60% |
| 2016 | $2.04B | 8.78% |
| 2015 | $1.88B | 17.41% |
| 2014 | $1.60B | 25.29% |
| 2013 | $1.28B | 18.63% |
| 2012 | $1.08B | 44.84% |
| 2011 | $742.34M | 40.70% |
| 2010 | $527.59M | 26.12% |
| 2009 | $418.31M | 42.04% |
| 2008 | $294.49M | 97.15% |
| 2007 | $149.37M | 58.30% |
| 2006 | $94.36M | -3.22% |
| 2005 | $97.50M | -27.90% |
| 2004 | $135.23M | 27.73% |
| 2003 | $105.87M | 19.26% |
| 2002 | $88.77M | 28.20% |
| 2001 | $69.24M | 37.37% |
| 2000 | $50.40M | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $2.54B | -48.08% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| $830.81M | -82.99% |
US
|
|
| - | - |
IT
|
